Triple-negative breast cancer [Triple-negative: hormone receptor (HR)–negative/human epidermal growth factor receptor 2 (HER2)–negative] and HER2+ breast cancer (HR-negative/HER2-positive) have a higher likelihood of developing brain metastasis, with rates of 25%–27% and 11%–20%, respectively. The gene discussed is ERBB2; the disease is breast cancer.